.02 on the NASDAQ. This SniperIQ fundamentals page covers Elicio Therapeutics's valuation, profitability (net margin 0.0%), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap$58M
Net Margin0.0%

Full research coverage

Frequently Asked Questions

What is Elicio Therapeutics's market cap?

Elicio Therapeutics (ELTX) has a market capitalization of approximately $58M, trading at

.02 on the NASDAQ. Market cap moves with the live share price.

How profitable is Elicio Therapeutics?

Elicio Therapeutics runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

Does Elicio Therapeutics pay a dividend?

Elicio Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Elicio Therapeutics financially healthy?

Elicio Therapeutics carries a debt-to-equity ratio of -9.98x and a current ratio of 2.24x, with a market beta of 1.78. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Elicio Therapeutics a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Elicio Therapeutics (ELTX) the key facts are: market cap $58M, 52-week range 2.66-16. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Elicio Therapeutics's full fundamentals live

Get Elicio Therapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.